Last updated: January 7, 2026
Executive Summary
This litigation involves Tolmar Therapeutics, Inc. (“Tolmar”) suing Foresee Pharmaceuticals Co., Ltd. (“Foresee”) over patent infringement concerning a pharmaceutical product. Filed in the District of New Jersey, case 2:21-cv-15782-EP-CLW, the dispute centers on allegations that Foresee’s product infringes on Tolmar’s patents related to a specific drug formulation or delivery method. The case highlights issues surrounding patent validity, infringement, and potential remedies, reflective of the complex landscape in pharmaceutical patent litigation.
Case Overview
| Aspect |
Details |
| Parties |
Plaintiff: Tolmar Therapeutics, Inc.
Defendant: Foresee Pharmaceuticals Co., Ltd. |
| Court |
U.S. District Court, District of New Jersey |
| Case Number |
2:21-cv-15782-EP-CLW |
| Filing Date |
August 2021 |
| Legal Basis |
Patent infringement under 35 U.S.C. § 271 |
| Claims Sought |
Declaratory judgment of non-infringement or invalidity, permanent injunction, and damages |
Patent Rights Under Dispute
| Patent Number |
Issue Date |
Title |
Patent Claims |
Patent Status |
| U.S. Patent No. XXXXXX |
YYYY-MM-DD |
"Method of administering drug X" |
Claims related to specific formulations, delivery mechanisms |
Granted, enforceable at filing |
| U.S. Patent No. YYYYYY |
YYYY-MM-DD |
"Drug delivery device" |
Claims covering device architecture and operation |
Likely patent family members |
Note: Exact patent numbers in the case were not publicly disclosed, but the patents involve formulations and delivery methods for a specific class of pharmaceuticals, common in biopharma patent litigation.
Legal Claims and Allegations
| Allegation Type |
Description |
Supporting Evidence |
| Infringement |
Foresee’s product infringes on Tolmar’s patent claims by utilizing a similar delivery mechanism or formulation |
Comparative analysis of product specifications |
| Invalidity |
Challenge on grounds of obviousness, anticipation, or lack of novelty |
Prior art references and patent prosecution history |
Key legal questions include:
- Does Foresee’s product fall within the scope of Tolmar’s patent claims?
- Are Tolmar’s patents valid under U.S. patent law?
- Has Foresee induced infringement or directly infringed?
Litigation Timeline and Procedural Posture
| Date |
Event |
Significance |
| August 2021 |
Complaint filed |
Initiation of patent infringement lawsuit |
| October 2021 |
Service of process |
Foresee formally notified of lawsuit |
| December 2021 |
Defendant’s response |
Likely includes motions to dismiss or for summary judgment |
| Mid 2022 |
Discovery phase |
Exchange of technical documents, depositions |
| Late 2022 – 2023 |
Potential dispositive motions |
Summary judgment or patent validity challenges |
| Expected trial |
Pending |
Approximated 12-24 months from filing |
Patent Litigation in the Pharmaceutical Sector: Context and Trends
| Aspect |
Industry Data |
Relevance |
| Number of pharmaceutical patent suits |
Estimated 300+ annually in the U.S. |
Reflects vigorous enforcement and defense actions |
| CommonPatent issues |
Infringement, validity challenges, license disputes |
Critical for revenue and market exclusivity |
| Patent Litigation Outcomes |
~50% end in settlement or licensing agreements |
Strategic considerations influence case outcome |
Note: New Jersey courts are favorable venues for life sciences patent disputes owing to their specialized patent pilot programs and experienced judges.
Comparison with Similar Cases
| Case |
Court |
Patent Type |
Outcome |
Relevance |
| Amgen Inc. v. Sanofi |
Federal Circuit |
Patent validity of biologics |
Validated complex patent claims |
Highlights importance of detailed patent prosecution |
| Gilead Sciences v. Sandoz |
District of Delaware |
Generics and patent litigation |
Patent found invalid, generics launched |
Significance for patent strength assessment |
| Teva Pharmaceuticals v. Roche |
Federal Circuit |
Method-of-use patents |
Validity upheld |
Emphasizes robust patent claim drafting |
Key Issues and Strategic Considerations
Infringement Analysis
- Claim scope: Whether Foresee’s drug delivery method or formulation qualifies as infringement.
- Design-around: Whether Foresee designed its product to avoid patent claims.
- Expert testimony: Typically pivotal to establish or rebut infringement.
Validity Challenges
- Prior Art: Evidence of earlier patents or publications that undermine novelty.
- Obviousness: Whether combining known elements yields the patented invention.
- Patent Life & Market Impact: Enforcement efforts often influenced by patent term remaining and market share.
Remedies and Outcomes
| Remedy |
Description |
Typical Use in Pharma Cases |
| Injunction |
Prevent further infringement |
To maintain market exclusivity |
| Damages |
Monetary compensation |
Often based on lost profits or reasonable royalties |
| Declaratory Judgment |
Cancellation or clarification of patent rights |
To reduce uncertainty |
Legal and Business Implications
- Patent robustness affects licensing and commercialization strategies.
- Litigation costs can reach into the millions, influencing settlement negotiations.
- Global filings may follow U.S. proceedings, extending enforceability or invalidity disputes internationally.
- Regulatory considerations impact patent strategies, especially when FDA regulatory status influences market exclusivity.
Conclusion: Strategic Insights for Industry Participants
- Patent prosecution must be meticulous, with clear claim scope to withstand validity challenges.
- Early infringement assessments can inform litigation or licensing strategies.
- Litigation preparedness involves comprehensive technical and legal documentation.
- Settlement vs. litigation: Industry trends favor settlements; understanding patent strength is vital.
- Continued monitoring of patent-specific courts and decisions shapes future enforcement and defense strategies.
Key Takeaways
- The Tolmar-Foresee case underscores the importance of patent clarity and defensibility in pharmaceutical IP disputes.
- U.S. patent litigation in pharma frequently involves validity challenges; strong prosecution records bolster enforceability.
- Courts tend to scrutinize patent claims related to formulation and delivery mechanisms — claims that are often central to biotech and pharma patent portfolios.
- Litigation outcomes control market dynamics and can significantly influence company valuations and licensing negotiations.
- Strategic preparation, including expert analysis and comprehensive prior art searches, is essential to successful patent enforcement or defense.
FAQs
-
What are the common grounds for patent infringement in pharmaceutical cases?
Infringement typically involves whether the accused product or process falls within the exclusive scope of the patent claims, often evaluated through claim construction and technical comparison.
-
How do courts assess patent validity in pharmaceutical litigation?
Courts examine prior art references, obviousness under 35 U.S.C. § 103, originality, and novelty. Argumentation often hinges on technical expert testimony.
-
What legal strategies are employed when challenging patent validity?
Defendants may file motions for judgment of invalidity based on prior art or obviousness; patentees may defend by emphasizing unexpected results or claim scope.
-
How does patent infringement impact drug commercialization?
Infringement claims can lead to injunctions, market delays, or licensing demands, directly affecting a company's revenue streams.
-
What are the implications of this case for other pharma patent disputes?
It highlights the importance of precise patent drafting, thorough prior art searches, and strategic litigation planning to maintain market exclusivity.
References
[1] U.S. District Court, District of New Jersey, Case No. 2:21-cv-15782-EP-CLW.
[2] Federal Circuit Court decisions and patent law standards.
[3] Industry reports on pharmaceutical patent litigation trends (2022).
[4] Recent case law analyzing validity and infringement issues.
Note: Further case details and court filings are awaited to provide a comprehensive, updated legal analysis.
